Ramen spectroscopy

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has opened a new center at its facility in Tewksbury, Mass., it announced today.

The device, named the Verisante Aura, uses Raman spectroscopy to measure levels of various biomarkers – including proteins, nucleic acids, and metabolites – in skin lesions. In initial clinical trials it distinguished between benign and malignant lesions with 100-percent sensitivity and 70-percent specificity.

ICAP Ocean Tomo has conducted due diligence to rate the strength of the patents and is marketing the portfolio to various healthcare and other companies that might be interested in commercializing the technology, which can be used to monitor a patient's blood glucose or substances in the brain and cerebrospinal fluid.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.